ReviewEuropean journal of pediatrics2008
Tuberculosis: drug resistance, fitness, and strategies for global control.
Review in European journal of pediatrics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.The Lancet. Infectious diseases · 2023Review
- Article
- An update of the suicide plasmid-mediated genome editing system in Corynebacterium glutamicum.Microbial biotechnology · 2019Article
- Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India.Scientific reports · 2019Article
- Article
- Nonmutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase.RNA (New York, N.Y.) · 2016Article
- Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.PLoS medicine · 2016Article
- Drug-Resistant Tuberculosis: Challenges and Progress.Infectious disease clinics of North America · 2016Review
- Article
- Comparative Analysis of Human B Cell Epitopes Based on BCG Genomes.BioMed research international · 2016Article
- Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2015Article
- Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy.Drugs · 2014Review
- Evolution and transmission of drug-resistant tuberculosis in a Russian population.Nature genetics · 2014Article
- Point-of-care system for detection of Mycobacterium tuberculosis and rifampin resistance in sputum samples.Journal of clinical microbiology · 2014Article
- Rifampicin Resistance: Fitness Costs and the Significance of Compensatory Evolution.Antibiotics (Basel, Switzerland) · 2013Review
- Bayesian estimation of mixture models with prespecified elements to compare drug resistance in treatment-naïve and experienced tuberculosis cases.PLoS computational biology · 2013Article
- Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.The Journal of infectious diseases · 2012Article
- Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2012Article
- Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin.Antimicrobial agents and chemotherapy · 2011Article
- Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Directly observed standardized short-course chemotherapy (DOTS) regimes are an effective treatment for drug susceptible tuberculosis disease. Surprisingly, DOTS has been reported to reduce the transmission of multi-drug resistant tuberculosis, and standardized short-course chemotherapy regimens with first-line agents have been found to be adequate treatments for some patients with drug resistant tuberculosis, including multi-drug resistance. These paradoxical observations and the apparent heterogeneity in treatment outcome of multi-drug resistant tuberculosis when using standard regimens may be due in part to limitations of in vitro drug susceptibility testing based on unique but mistakenly used techniques in diagnostic mycobacteriology. Experimental data and mathematical models indicate that the fitness cost conferred by a resistance determinant is the single most important parameter which determines the spread of drug resistance. Chromosomal alterations that result in resistance to first-line antituberculosis agents, e.g. isoniazid, rifampicin, streptomycin, may or may not be associated with a fitness cost. Based on work in experimental models and from observations in clinical drug resistant isolates a picture emerges in which, among the various resistance mutations that appear with similar rates, those associated with the least fitness cost are selected in the population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.